Literature DB >> 19058855

Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme.

Wing Yau1, Roxanne J Owen, Anima Poudyal, Jan M Bell, John D Turnidge, Heidi H Yu, Roger L Nation, Jian Li.   

Abstract

BACKGROUND: Multidrug-resistant Acinetobacter baumannii has presented a global medical problem. Emergence of colistin resistance, including hetero-resistance, has been increasingly reported. This study examined the susceptibility to colistin of multidrug-resistant A. baumannii from the Western Pacific region.
METHODS: A total of 30 isolates were studied from 10 clinical centres in various countries. MICs were measured against 21 antibiotics by broth microdilution. Colistin population analysis profiles (PAPs) (0, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10mg/L) were determined. Time-kill kinetics of colistin against 3 isolates (2 colistin-susceptible (one of which was colistin hetero-resistant) and 1 colistin-resistant) were studied over a wide range of concentrations and development of resistance was monitored by measurement of colistin PAPs after 24-h exposure.
RESULTS: All the isolates were highly multiresistant. Colistin MICs were 0.5-2mg/L except one isolate which had an MIC of 128mg/L. Seven isolates were colistin hetero-resistant with subpopulations growing at >2mg/L. For the 2 colistin-susceptible isolates examined, >3log killing was observed within 3h even at 0.5x MIC. Interestingly, >3log killing was also observed with the colistin-resistant isolate within 1h even at 0.5mg/L. Regrowth occurred at 24h for both colistin-susceptible and -resistant isolates. Emergence of resistance to colistin after 24-h exposure was confirmed by PAP.
CONCLUSION: Colistin was very active against A. baumannii based upon MICs and initial killing in time-kill studies. Hetero-resistance in this group of A. baumannii isolates was less common than in previous studies. Nevertheless, care is required with colistin monotherapy for A. baumannii infections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19058855     DOI: 10.1016/j.jinf.2008.11.002

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  43 in total

1.  fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.

Authors:  Rajesh V Dudhani; John D Turnidge; Roger L Nation; Jian Li
Journal:  J Antimicrob Chemother       Date:  2010-06-23       Impact factor: 5.790

Review 2.  Dosing of colistin-back to basic PK/PD.

Authors:  Phillip J Bergen; Jian Li; Roger L Nation
Journal:  Curr Opin Pharmacol       Date:  2011-08-09       Impact factor: 5.547

3.  In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations.

Authors:  Pilar Escribano; Sandra Recio; Teresa Peláez; Milagros González-Rivera; Emilio Bouza; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

4.  Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model.

Authors:  Xingchen Bian; Xiaofen Liu; Yuancheng Chen; Daijie Chen; Jian Li; Jing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 5.  Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations.

Authors:  Fereshteh Ezadi; Abdollah Ardebili; Reza Mirnejad
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

Review 6.  Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.

Authors:  Laurent Poirel; Aurélie Jayol; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

7.  The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Zakuan Z Deris; Heidi H Yu; Kathryn Davis; Rachel L Soon; Jovan Jacob; Caron K Ku; Anima Poudyal; Phillip J Bergen; Brian T Tsuji; Jurgen B Bulitta; Alan Forrest; David L Paterson; Tony Velkov; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

8.  Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.

Authors:  Phillip J Bergen; Alan Forrest; Jürgen B Bulitta; Brian T Tsuji; Hanna E Sidjabat; David L Paterson; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

9.  Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Hee Ji Lee; Phillip J Bergen; Jurgen B Bulitta; Brian Tsuji; Alan Forrest; Roger L Nation; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

10.  Synthesis of Norbornane Bisether Antibiotics via Silver-mediated Alkylation.

Authors:  Shane M Hickey; Trent D Ashton; Jonathan M White; Jian Li; Roger L Nation; Heidi Y Yu; Alysha G Elliott; Mark S Butler; Johnny X Huang; Matthew A Cooper; Frederick M Pfeffer
Journal:  RSC Adv       Date:  2015       Impact factor: 3.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.